Voriconazole vs Itraconazole for Primary Prophylaxis of Invasive Fungal Infection (IFI) in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients

D. I. MARKS¹, C. KIBBLER², A. PAGLIUCA³, P. RIBAUD⁴, C. SOLANO⁵, C. P. HEUSSEL⁶, G. COOK⁷, A. GLASMACHER⁸, H. SCHLAMM⁹, M. KANTECKI⁹, Improvit Study Group;

¹UH Bristol, Bristol, United Kingdom, ²Royal Free H, London, United Kingdom, ³King's Coll H, London, United Kingdom, ⁴H Saint-Louis, Paris, France, ⁵H Clínico, Valencia, Spain, ⁶Radiology, Thoraxklinik at Univ H, Heidelberg, Germany, ⁷St James' Univ H, Leeds, United Kingdom, ⁸Univ klinikum Bonn, Bonn, Germany, ⁹Pfizer Inc, New York, NY.

Funding: Study and editorial support sponsored by Pfizer Inc.

Abstract

Background: Optimal antifungal prophylaxis following HCT is uncertain. The potential of oral VOR required prospective randomized evaluation.

Methods: Prospective, open label, multicenter study for primary IFI prophylaxis after allogeneic HCT. Patients >= 12 years were randomized (stratified by conditioning regimen intensity and donor type) to receive oral VOR or oral ITR from the day of HCT for at least 100 and up to 180 days. Primary composite endpoint: success of prophylaxis at Day 180, i.e. patient survived without developing proven/probable IFI or discontinuing prophylaxis for > 14 days during the first 100 days.

Results: 234 patients were randomized to VOR and 255 to ITR; all received > 1 dose of study drug. Success of prophylaxis was significantly higher with VOR than with ITR at Days 100 (55% vs 41%; adjusted 95% CI for difference: 6%, 24%; p=0.0007) and 180 (49% vs 35%; adjusted 95% CI for difference: 7%, 24%; p=0.0004). Significantly more VOR than ITR (54% vs 40%; p=0.0014) patients had sufficient days of prophylaxis (median: 97 vs 68 days). IFI incidence was low in both arms (VOR: 1.3%, ITR: 2.0%); no patients developed IFI while receiving VOR, compared with 3 ITR patients. There was no difference in 180 day survival (85% each). The most common treatment-related adverse events for VOR and ITR, respectively, were nausea (8% vs 15%), diarrhoea (4% vs 11%), hepatotoxicity (7% vs 2%) and visual impairment (6% vs 0%).

Conclusions: Primary prophylaxis with VOR is an effective, safe option for preventing IFI after allogeneic HCT.
Background

• Invasive aspergillosis (IA) is the major fungal threat in allogeneic HCT recipients
  – Voriconazole is an established and effective therapy for documented IA
• Optimal antifungal prophylaxis following allogeneic HCT is uncertain
• Oral antifungal agents have potential advantages but require testing in the allograft setting
• Oral voriconazole required prospective randomized evaluation as antifungal prophylaxis against an established oral agent that covers moulds
Prospective, Open-Label, Multicenter Study

- 489 patients ≥ 12 years of age undergoing allogeneic HCT (myeloablative or reduced intensity)
- Randomized to primary IFI prophylaxis, stratified by conditioning regimen and donor type

**Voriconazole (N=234)**
- IV loading dose: 6 mg/kg BID
- PO maintenance dose: 200 mg BID for patients >40 kg and 100 mg BID for those <40 kg

**Itraconazole (N=255)**
- IV loading dose: 200 mg BID
- PO maintenance dose: 200 mg BID (Itraconazole capsules for total of ≤14 days only, ≤5 day periods suggested)

- Duration: at least 100 and up to 180 days
- Empirical therapy with non-study antifungal agent was permitted if signs of possible IFI developed

**Participating countries:** UK, Spain, France, Canada, Czech Republic, Portugal, Switzerland, Egypt, Greece, Russia, Turkey, Jordan
Primary Endpoint

Success of antifungal prophylaxis, defined as:

- Survival at 180 days post-transplant **AND**
- No proven or probable breakthrough IFI **AND**
- No discontinuation of study drug for >14 days during 100 day prophylactic period

Primary analysis was intended to demonstrate non-inferiority of voriconazole at Day 180. If non-inferiority was shown, superiority was tested. Non-inferiority = lower limit of two-sided 95% confidence interval (CI) for difference in adjusted success rates is above -10%. Superiority = two-sided 95% CI does not include 0% and is positive.
Success of Antifungal Prophylaxis at Day 180 (Primary Endpoint)

Voriconazole met criteria for non-inferiority and superiority

* Difference in proportions (Voriconazole – Itraconazole) adjusted for conditioning regimen (myeloablative vs. non-myeloablative) and relatedness of donor (matched related donor vs. mismatched/unrelated donor)
Survival

Day 100

Voriconazole: 219 (94%) with N=234
Itraconazole: 240 (94%) with N=255

Day 180

Voriconazole: 199 (85%) with N=234
Itraconazole: 217 (85%) with N=255
**Sufficient Duration of Prophylaxis**

- **Voriconazole**: 127 (54.3%) of 234 patients did not discontinue study drug for >14 days in total prior to Day 100.
- **Itraconazole**: 102 (40.0%) of 255 patients did not discontinue study drug for >14 days in total prior to Day 100.

**Difference in Proportions (Voriconazole – Itraconazole)**

- Median Duration of therapy: Voriconazole = 97 days; Itraconazole = 68 days.

- **14.3% (95% CI: 5.5% to 23.0%; P<0.01)**

* Sufficient duration of prophylaxis = patient did not discontinue study drug for >14 days in total prior to Day 100.

** Difference in proportions (Voriconazole – Itraconazole).
## IFIs During Study

<table>
<thead>
<tr>
<th>EORTC criteria</th>
<th>Treatment Emergent*</th>
<th>Pathogen</th>
<th>Body Site of IFI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3 in Voriconazole arm</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proven</td>
<td>No</td>
<td><em>Candida krusei</em></td>
<td>Blood</td>
</tr>
<tr>
<td>Proven</td>
<td>No</td>
<td><em>Candida parapsilosis</em></td>
<td>Blood</td>
</tr>
<tr>
<td>Probable</td>
<td>No</td>
<td><em>Aspergillus fumigatus</em></td>
<td>Lung</td>
</tr>
<tr>
<td><strong>6 in Itraconazole arm</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proven</td>
<td>Yes</td>
<td><em>Candida glabrata</em></td>
<td>Blood</td>
</tr>
<tr>
<td>Proven</td>
<td>No</td>
<td><em>Aspergillus fumigatus</em></td>
<td>Lung</td>
</tr>
<tr>
<td>Probable</td>
<td>Yes</td>
<td><em>Aspergillus sp</em></td>
<td>Lung</td>
</tr>
<tr>
<td>Probable</td>
<td>Yes</td>
<td><em>Aspergillus sp</em></td>
<td>Lung</td>
</tr>
<tr>
<td>Probable</td>
<td>No</td>
<td><em>Aspergillus fumigatus</em></td>
<td>Lung</td>
</tr>
<tr>
<td>Probable</td>
<td>No</td>
<td><em>Aspergillus sp</em></td>
<td>Lung</td>
</tr>
</tbody>
</table>

*Treatment-emergent IFIs: occurring any time while patient was on study drug and for 7 days following treatment discontinuation.

Treatment-emergent IFIs: Voriconazole 0%, Itraconazole 1.2% (P=0.08 for difference).
Most Common Treatment-Related Adverse Events (≥5% in Either Group)

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Voriconazole N=234</th>
<th>Itraconazole N=255</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>9 (4%)</td>
<td>40 (16%)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Nausea</td>
<td>18 (8%)</td>
<td>38 (15%)</td>
<td>0.01</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>10 (4%)</td>
<td>28 (11%)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Headache</td>
<td>11 (5%)</td>
<td>13 (5%)</td>
<td>0.84</td>
</tr>
<tr>
<td>Visual impairment</td>
<td>14 (6%)</td>
<td>0 (0%)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Hepatotoxicity/Liver function test abnormality</td>
<td>29 (12%)</td>
<td>12 (5%)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>
Summary of Major Findings

• Success of prophylaxis was significantly higher with voriconazole than with itraconazole in allogeneic HCT recipients.
• There was no significant difference between the 2 treatments in terms of survival and IFI incidence.
• The proportion of patients able to stay on prophylaxis for a sufficient duration was significantly higher with voriconazole than with itraconazole.
• Hepatotoxicity was more common with voriconazole, but occurred at rates consistent with previous reports in this study population.
• Long-term primary prophylaxis with voriconazole is an effective, safe option for preventing IFIs following allogeneic HCT.
Acknowledgements

• Peter Troke
• Iwonka Oborska
• Paul Miller, Statistician

The authors would like to thank all investigators who recruited patients into the study, as well as the study team for its invaluable contributions